ERBB2 and breast carcinoma: A phase II study for heavily pretreated patients with HER2-positive breast cancer revealed promising efficacy for trastuzumab deruxtecan at a dose of 5.4 mg/kg, with an ORR and a DCR of 60.9% and 97.3%, respectively [60].